RecruitingPhase IIEN originalHead and neck cancer

Toripalimab With Chemotherapy for Sinus Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this research study are: * Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • •Potwierdzony histologicznie lub cytologicznie rak jamy nosowej lub zatok przynosowych (typ komórkowy: rak płaskonabłonkowy lub niedifferentiowany)
  • •Wiek 18 lat lub więcej
  • •Choroba na zaawansowanym lokalnym stadium, kwalifikująca się do operacyjnego usunięcia
  • •Dobra funkcja wątroby, nerek i szpiku kostnego potwierdzona badaniami krwi
  • •Chęć do pobrania próbek krwi i tkanki przed leczeniem i podczas operacji
  • •Ogólny stan zdrowia pozwalający na tolerowanie leczenia (status performance 0-1)
  • •Kobiety i mężczyźni w wieku rozrodczym muszą stosować antykoncepcję przez czas badania

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 31, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (2)

Brigham and Women's Hospital

Boston, United States

Dana-Farber Cancer Institute

Boston, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.